Blood advances : Impact Factor & More
eISSN: 2473-9537pISSN: 2473-9529
Share this on:
Key Metrics
CiteScore 
9.6
Eigenfactor
0.01 - 0.05
H-Index
69
Impact Factor
5 - 10
Scite Index
0.89 5-Year SI
SJR
Q1Hematology
SNIP
1.95
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Blood advances
Blood advances Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | ELSEVIER |
| Language | English |
| Frequency | Semi-monthly |
| General Details | |
| Language | English |
| Frequency | Semi-monthly |
| Publication Start Year | 2016 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Blood advances ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Blood advances
Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study.
- 26 May 2026
- Blood advances
Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.
- 26 May 2026
- Blood advances
Hematopoietic JAK2V617F mutation-induced reprogramming of blood and bone marrow megakaryocytes.
- 26 May 2026
- Blood advances
Total body irradiation and smoking interact to increase lung cancer risk after blood or marrow transplantation.
- 26 May 2026
- Blood advances
A revised classification of FVIII concentrates: rationale and novel metrics.
- 26 May 2026
- Blood advances
A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.
- 26 May 2026
- Blood advances
Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study.
- 26 May 2026
- Blood advances
Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.
- 26 May 2026
- Blood advances
Hematopoietic JAK2V617F mutation-induced reprogramming of blood and bone marrow megakaryocytes.
- 26 May 2026
- Blood advances
Total body irradiation and smoking interact to increase lung cancer risk after blood or marrow transplantation.
- 26 May 2026
- Blood advances
A revised classification of FVIII concentrates: rationale and novel metrics.
- 26 May 2026
- Blood advances
A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.
- 26 May 2026
- Blood advances
FAQs on Blood advances
How long has Blood advances been actively publishing? 
What is the publishing frequency of Blood advances?
How many articles did Blood advances publish last year?
What is the eISSN & pISSN for Blood advances?
What is Citescore for Blood advances?
What is the H Index for Blood advances ?
What is SNIP score for Blood advances?
What is the SJR for Blood advances?
Who is the publisher of Blood advances?
